CN102342415A - Composition capable of improving gastrointestinal tract function and assisting lowering of blood sugar and blood lipid - Google Patents
Composition capable of improving gastrointestinal tract function and assisting lowering of blood sugar and blood lipid Download PDFInfo
- Publication number
- CN102342415A CN102342415A CN201110304764.6A CN201110304764A CN102342415A CN 102342415 A CN102342415 A CN 102342415A CN 201110304764 A CN201110304764 A CN 201110304764A CN 102342415 A CN102342415 A CN 102342415A
- Authority
- CN
- China
- Prior art keywords
- composition
- oligosaccharides
- blood
- blood sugar
- assisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a composition, which is mainly characterized by being prepared by processing 30.0-50.0% of chitosan oligosaccharides (COS), 10.0-30.0% of mannose oligosaccharides (MOS), 5.0-15.0% of protein hydrolyzate (oligopeptide), 1.0-5.0% of grape seed extract and 0.01-0.02% of natural astaxanthin (ASTA) by weight percent. The composition can promote the significant proliferation of bacillus bifidus, bacterium lacticum and other beneficial flora in the intestinal tract, and lower blood sugar and blood lipid and improve human immunity on the basis of improving the micro-ecological environment of intestinal tract.
Description
Technical field
The invention belongs to the functional food technical field, be specifically related to a kind of auxiliary composition that reduces blood sugar and blood fat of gastrointestinal function that improves, is on the basis of improving the intestinal microecology environment, to reduce blood sugar, blood fat, the composition of enhancing human immune.
Background technology
Existing document and patent utilization compound sugar improve gut flora, reach the purpose that reduces blood sugar and blood fat, like fourth Soviet Union (< microwave synthesis of oligonucleotides wood sugar and anti-oxidant and effect for reducing blood fat research thereof >, Southern Yangtze University's journal, on June 1st, 2008); Patent documentation: CN 101559802A, 2009.10.21.
Above-mentioned technology and product have following deficiency: the bacterial classification in a. active bacteria formulation is single; And flora is a complicated system in the human body intestinal canal; Next is that active bacteria formulation is the manufactured goods of laboratory bacterial classification; And use compatible very poor between the individuality; Secondly there is certain problem in the safe preservation that is product, fortune, lock ring joint again, particularly also has the potential risk of bacterial classification variation; B. FOS of using in the present product and xylo-oligosaccharide are low middle-grade products.They have only 5～10 times to the cultivation effect of Bifidobacterium, lactobacillus; Can't directly reduce harmful bacterium such as enterobacteria; Using these products one and be need very big using dosage; The 2nd, also have the material of the changed into energy more than 50% in these products; Be unfavorable for regulating blood pressure and blood lipoid; Harm to obesity and diabetic is bigger, thereby has limited the application crowd of product.Utilize mannan-oligosaccharides, chitooligosaccharide-to be Main Ingredients and Appearance, be used for the technology of reducing blood lipid again with protein hydrolysate (oligopeptides) combination, be not reported.
Summary of the invention
The purpose of this invention is to provide a kind of by compound sugar, oligopeptides, grape seed extract and natural astaxanthin etc. form can auxiliary antilipemic composition; Improve human body intestinal canal flora; Reach reducing blood lipid, improve body immunity, promote human body constitution and the purpose of improving health condition of people comprehensively.
For reaching above purpose; Technical scheme of the present invention is by chitooligosaccharide-; Mannan-oligosaccharides; Protein hydrolysate (oligopeptides); Grape seed extract; Natural astaxanthin is formed; Its content is by weight percentage: chitooligosaccharide-(Chitosan oligosaccharides; COS) 30.0% ~ 50.0%; Mannan-oligosaccharides (Mannose oligosaccharides; MOS) 10.0% ~ 30.0%; Protein hydrolysate (oligopeptides) 5.0% ~ 15.0%; Grape seed extract 1.0% ~ 5.0%; Natural astaxanthin (Astaxanthin; ASTA) 0.01% ~ 0.02%, all the other auxiliary material dextrin.
In order to achieve the above object, the method that composition is made into capsule-type is:
Batch mixing.With the manna oligosacchride in the composition, chitooligosaccharide-, protolysate (oligopeptides), grape seed extract (powdery), each formula components such as natural astaxanthin WZL800 type Agravicmixer of packing into makes it to mix.
It is dry to granulate.The composition of above-mentioned mixing is changed over to the drying of granulating in dry (boiling granulating) machine of LGL200 type fluidized bed granulation.
Screening.The composition of having granulated is changed in the ZS-400 shaking screen, select 80 ~ 120 order materials to change down operation over to.
Canned.Canned the composition that had sieved with the capsule can packing machine.
Detecting packing dispatches from the factory.
The specific embodiment
The present invention is by chitooligosaccharide-; Mannan-oligosaccharides; Protein hydrolysate (oligopeptides); Biological active calcium; Lucidum spore powder is processed through processing; Its content is by weight percentage: chitooligosaccharide-(Chitosan oligosaccharides; COS) 30.0% ~ 50.0%; Mannan-oligosaccharides (Mannose oligosaccharides; MOS) 10.0% ~ 30.0%, protein hydrolysate (oligopeptides) 5.0% ~ 15.0%, grape seed extract 1.0% ~ 5.0%; Natural astaxanthin (Astaxanthin, ASTA) 0.01% ~ 0.02%.
Embodiment one
Capsule formula (350mg/ grain)
1、COS：45%，157.5mg
2、MOS：30%，105mg
3, protein hydrolysate (oligopeptides): 15%, 52.5mg
4, grape seed extract: 5%, 17.5mg
5, astaxanthin: 0.01%, 0.035mg
All the other auxiliary material dextrin.
Production process:
1, batch mixing.With each formula components such as the manna oligosacchride in the composition, chitooligosaccharide-, protolysate (oligopeptides), lucidum spore powder and biological active calcium WZL800 type Agravicmixer of packing into, make it to mix.
2, granulation is dry.The composition of above-mentioned mixing is changed over to the drying of granulating in dry (boiling granulating) machine of LGL200 type fluidized bed granulation.
3, screening.The composition of having granulated is changed in the ZS-400 shaking screen, select the material of 80 ~ 120 orders (0.18 μ m ~ 0.125 μ m) to change down operation over to.
4, canned.Canned the composition that had sieved with the capsule can packing machine.
5, detect, pack, dispatch from the factory.
Embodiment two
Capsule formula (350mg/ grain)
1、COS：50%，175mg
2、MOS：25%，87.5mg
3, protein hydrolysate (oligopeptides): 15%, 52.5mg
4, grape seed extract: 4.99%, 17.465mg
5, astaxanthin: 0.01%, 0.035mg
All the other auxiliary material dextrin.
Production process is identical with embodiment 1
Embodiment three
Gut flora changed testing result before and after human body was taken said composition
* compare P＜0.01 with edible preceding relatively P＜0.05 * * and before eating
Show through the test of bodily fuctions's property; Said composition can make the quantity of Bifidobacterium, lactobacillus in the human body significantly increase; Difference has utmost point Xian Zhu Xing ﹙ P＜0.01 ﹚; The quantity of bacteroid obviously increases; Difference has Xian Zhu Xing ﹙ P＜0.05 ﹚; Enterobacteria quantity obviously reduces, and difference has utmost point Xian Zhu Xing ﹙ P＜0.01 ﹚, and the quantity of enterococcus, C.perfringens does not have significant change.
Embodiment four
Composition is to the influence of human body reducing blood lipid
Remarks:
1. sugar juice total reducing sugar＞30%, no crystallization forms, oligosaccharide content in the total reducing sugar >=95%.
2. TG: if increase: possibly suffer from coronary heart disease, diabetes, nephrotic syndrome, congenital lipoprotein lipase defective, fatty liver etc.
If lower: possibly suffer from hyperthyroidism, the serious depletion of liver function etc.
3. TC: if increase: possibly suffer from atherosclerotic, nephrotic syndrome, choledochus obstruction, diabetes, myxedema etc.
If lower: possibly suffer from hyperthyroidism, pernicious anaemia, hemolytic anemia etc.
4. HDL-C: if lower: possibly suffer from coronary heart disease, atherosclerotic.
Because of it is called the protection factor of coronary heart disease, so anti-useful when increasing.
5. SOD: can remove the murder by poisoning of oxygen radical, strengthen diseases prevention, anti-inflammatory, antitumor, radioresistance, antioxygen is poisoned and effect such as anti-autoimmune disease to human body.
6. LPO: interior free radical too much can cause the chain reaction of lipid peroxidation, forms lipid peroxide (LPO), thereby causes cell ageing.
Compare with existing procucts, the present invention has the gut flora of adjusting, auxiliary antilipemic, raising immunity, strengthens the effect of vitality comprehensively.
Claims (1)
1. one kind is improved the auxiliary composition that reduces blood sugar and blood fat of gastrointestinal function; It is characterized in that said composition is filled a prescription by weight percentage is: chitooligosaccharide-(Chitosan oligosaccharides; COS) 30.0% ~ 50.0%; Mannan-oligosaccharides (Mannose oligosaccharides; MOS) 10.0% ~ 30.0%; Protein hydrolysate (oligopeptides) 5.0% ~ 15.0%; Grape seed extract 1.0% ~ 5.0%; Natural astaxanthin (Astaxanthin; ASTA) 0.01% ~ 0.02%, all the other auxiliary material dextrin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110304764.6A CN102342415B (en) | 2011-10-10 | 2011-10-10 | Composition capable of improving gastrointestinal tract function and assisting lowering of blood sugar and blood lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110304764.6A CN102342415B (en) | 2011-10-10 | 2011-10-10 | Composition capable of improving gastrointestinal tract function and assisting lowering of blood sugar and blood lipid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102342415A true CN102342415A (en) | 2012-02-08 |
| CN102342415B CN102342415B (en) | 2013-06-05 |
Family
ID=45541793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110304764.6A Expired - Fee Related CN102342415B (en) | 2011-10-10 | 2011-10-10 | Composition capable of improving gastrointestinal tract function and assisting lowering of blood sugar and blood lipid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102342415B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102960520A (en) * | 2012-11-29 | 2013-03-13 | 山东福田科技集团有限公司 | L-arabinose health-care press candy added with cyclocarya paliurus |
| CN103431401A (en) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | Antioxidant health care food and application thereof |
| WO2014208511A1 (en) * | 2013-06-27 | 2014-12-31 | 学校法人同志社 | Intestinal flora improving composition containing astaxanthin |
| CN105533753A (en) * | 2015-12-29 | 2016-05-04 | 徐州市铜山区生命科学研究院 | Medicinal and edible microcirculation obstacle preventing and curing compound nutrient |
| CN105920054A (en) * | 2016-03-23 | 2016-09-07 | 李燕铭 | Medical health care product for resisting antioxidation, delaying aging and preventing tumorigenesis |
| CN107279740A (en) * | 2017-06-22 | 2017-10-24 | 合肥市晶谷米业有限公司 | A kind of health-care rice |
| CN107296281A (en) * | 2017-07-18 | 2017-10-27 | 迪沙药业集团有限公司 | A kind of lipid-lowering health food |
| CN108618134A (en) * | 2018-05-03 | 2018-10-09 | 江苏二十维生物科技有限公司 | A kind of healthy diet intervention product and its preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101053409A (en) * | 2007-05-11 | 2007-10-17 | 汪昔奇 | Health care food containing natural astaxanthin |
| CN101715913A (en) * | 2008-12-02 | 2010-06-02 | 天津天狮生物发展有限公司 | Vivocon capsule and production process thereof |
-
2011
- 2011-10-10 CN CN201110304764.6A patent/CN102342415B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101053409A (en) * | 2007-05-11 | 2007-10-17 | 汪昔奇 | Health care food containing natural astaxanthin |
| CN101715913A (en) * | 2008-12-02 | 2010-06-02 | 天津天狮生物发展有限公司 | Vivocon capsule and production process thereof |
Non-Patent Citations (1)
| Title |
|---|
| 《林产化工通讯》 19991231 洪枫 等 新型功能性低聚糖的生产与研究 第14-20页 1 第33卷, 第4期 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102960520A (en) * | 2012-11-29 | 2013-03-13 | 山东福田科技集团有限公司 | L-arabinose health-care press candy added with cyclocarya paliurus |
| CN102960520B (en) * | 2012-11-29 | 2014-10-29 | 山东福田科技集团有限公司 | L-arabinose health-care press candy added with cyclocarya paliurus |
| WO2014208511A1 (en) * | 2013-06-27 | 2014-12-31 | 学校法人同志社 | Intestinal flora improving composition containing astaxanthin |
| CN103431401A (en) * | 2013-09-16 | 2013-12-11 | 厦门中药厂有限公司 | Antioxidant health care food and application thereof |
| CN103431401B (en) * | 2013-09-16 | 2015-03-11 | 厦门中药厂有限公司 | Antioxidant health care food and application thereof |
| CN105533753A (en) * | 2015-12-29 | 2016-05-04 | 徐州市铜山区生命科学研究院 | Medicinal and edible microcirculation obstacle preventing and curing compound nutrient |
| CN105533753B (en) * | 2015-12-29 | 2018-03-30 | 徐州市铜山区生命科学研究院 | A kind of compound nutritional agent of medicine-food two-purpose preventing and treating microcirculation disorder |
| CN105920054A (en) * | 2016-03-23 | 2016-09-07 | 李燕铭 | Medical health care product for resisting antioxidation, delaying aging and preventing tumorigenesis |
| CN107279740A (en) * | 2017-06-22 | 2017-10-24 | 合肥市晶谷米业有限公司 | A kind of health-care rice |
| CN107296281A (en) * | 2017-07-18 | 2017-10-27 | 迪沙药业集团有限公司 | A kind of lipid-lowering health food |
| CN108618134A (en) * | 2018-05-03 | 2018-10-09 | 江苏二十维生物科技有限公司 | A kind of healthy diet intervention product and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102342415B (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102342415B (en) | Composition capable of improving gastrointestinal tract function and assisting lowering of blood sugar and blood lipid | |
| González-Ferrero et al. | Soybean protein-based microparticles for oral delivery of probiotics with improved stability during storage and gut resistance | |
| AU2008251346B2 (en) | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same | |
| CN107115364B (en) | A kind of compound probiotic and preparation method thereof | |
| Kumari et al. | Fostering next-generation probiotics in human gut by targeted dietary modulation: An emerging perspective | |
| JP7330667B2 (en) | Gold kiwifruit composition and method of preparation and use thereof | |
| EP1481682B1 (en) | Preparation that contains oligosaccharides and probiotics | |
| Dixit et al. | Patents in the field of probiotics, prebiotics, synbiotics: a review | |
| RU2504211C2 (en) | Composition of soluble indigestible fibres and eukaryotic organisms with polysaccharide wall, applicable in health field | |
| Majeed et al. | Cranberry seed fibre: a promising prebiotic fibre and its fermentation by the probiotic Bacillus coagulans MTCC 5856 | |
| IL224833A (en) | Synbiotic product | |
| EP1917869A1 (en) | Probiotic/non-probiotic combinations | |
| Bao et al. | Structural characteristics and prebiotic effects of Semen coicis resistant starches (type 3) prepared by different methods | |
| JP2003250528A (en) | Survival-improving agent of bacterium belonging to the genus bifidobacterium, proliferation-promoting agent, or method for producing fermentation product containing the bacterium | |
| CN110506106A (en) | With the active novel strain and application thereof for reducing advanced glycation end products | |
| CN105249480A (en) | Chewable tablet with dietary fiber and bifidobacteria and preparing method thereof | |
| CN106954862A (en) | Edible fiber products and preparation method thereof | |
| KR101955775B1 (en) | Functional fermented food additive and functionality health food manufacturing method | |
| JP5372656B2 (en) | Metabolic syndrome improving composition | |
| Li et al. | Impacts of supplementation of probiotics on the prevalence of grape marc derived polyphenols in colonic digesta using in vitro digestion model | |
| CN106490285A (en) | A kind of preventing decayed tooth health-care sweets containing lactoferrin and preparation method thereof | |
| KR101487431B1 (en) | The manufacturing method of microcoated probiotics to use vegetable mucin and soluble dietry fiber | |
| JP5548393B2 (en) | Method for producing fermented grapes | |
| US20200316141A1 (en) | Composition To Support Healthy Brain Function | |
| CN111466579A (en) | Probiotic inulin tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210121 Address after: Room 802, building 10, Shenzhen Bay science and technology ecological park, No. 10, Gaoxin South 9th Road, high tech Zone community, Yuehai street, Nanshan District, Shenzhen, Guangdong 518000 Patentee after: Shenzhen lvtianqi biomedical Co.,Ltd. Address before: 430010 No. 975, Jianshe Avenue, Jiang'an District, Hubei, Wuhan Patentee before: WUHAN EAST ANGEL BIOENGINEERING Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130605 Termination date: 20211010 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |